|
Jun 24
|
Johnson & Johnson (JNJ): What Made this Healthcare Giant Get a Positive Analyst Outlook in Q1?
|
|
Jun 24
|
Do Options Traders Know Something About Johnson & Johnson (JNJ) Stock We Don't?
|
|
Jun 22
|
3 High-Yield Dividend Stocks Near Their 52-Week Lows to Buy and Hold
|
|
Jun 22
|
2 Top Stocks to Buy Now for Years of Passive Income
|
|
Jun 21
|
The 30-stock secret: ‘Don’t fight Papa Dow’
|
|
Jun 21
|
Top Midday Stories: Boeing Close to Buying Back Spirit AeroSystems; Amazon Plans to Launch Premium Alexa; Lockheed Sanctioned by China; American Express Acquires Tock From Squarespace
|
|
Jun 21
|
J&J (JNJ) Seeks Expanded Use of Tremfya for Crohn's Disease
|
|
Jun 21
|
The Zacks Analyst Blog Highlights Pfizer, Johnson & Johnson and Eli Lilly
|
|
Jun 21
|
Johnson & Johnson Completes Acquisition of Proteologix, Inc.
|
|
Jun 21
|
Johnson & Johnson seeks FDA approval for Tremfya for Crohn’s disease
|
|
Jun 21
|
J&J creates open digital platform for surgical applications
|
|
Jun 20
|
Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the treatment of moderately to severely active Crohn's disease
|
|
Jun 17
|
Johnson & Johnson’s nipocalimab shows promise in Sjögren’s disease trial
|
|
Jun 15
|
Late-breaking results show nipocalimab significantly improves Sjögren's disease activity in a Phase 2 study
|
|
Jun 14
|
TALVEY® (talquetamab-tgvs) demonstrates highly durable, longer-term responses in patients with relapsed or refractory multiple myeloma
|
|
Jun 12
|
A Life Expansion Revolution Is Coming: 3 Stocks That Could Lead the Charge
|
|
Jun 12
|
2 Stocks You Can Safely Hold for the Long Haul
|
|
Jun 11
|
Sector Update: Health Care Stocks Softer Late Afternoon
|
|
Jun 11
|
Johnson and Johnson Talcum-Settlement Consent Judgments Filed
|
|
Jun 11
|
Johnson & Johnson reaches $700 million talc settlement with US states
|